Rochester NY, 16 February 17, 2024 – RESILIÉLLETM Cosmetics LLC, a leader in innovative skincare and haircare solutions, proudly welcomes to the company Dr. Carla Mazzeo PhD, a global authority in exosome research who has more than 30 publications. She will spearhead company advancements in exosome-based skin, scalp, and hair care. Dr. Mazzeo, a leader in exosome research since 2004, was a Director and Senior Scientific Researcher at Boston University and Boston University Medical Center. She brings unparalleled expertise to enhance RESILIÉLLE’s commitment to excellence. [Read more…]
Stem Cells Surpass Landmark Milestone of 500K Scientific Publications
Wow, a tremendous achievement has been accomplished by the stem cell community. We have officially surpassed 500,000 publications about stem cells on PubMed.gov! PubMed is a service of the U.S. National Library of Medicine and NIH that comprises more than 27 million citations for biomedical literature. It is the largest and most comprehensive global database that exists for scientific publications anywhere in the world. [Read more…]
PeptiGrowth Inc. is launching a Novel Synthetic Peptide TPO-alternative peptide (TPOR agonist)
March 26, 2024, Chiyoda-ku, Tokyo – PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed a novel synthetic peptide called “TPO alternative peptide (TPOR agonist)” which has equivalent function to recombinant TPO (Thrombopoietin). This product will be on the market at the end of March 2024. [Read more…]
Endonovo Therapeutics Files Patent Application for Cell Therapy Created Using Cord Blood and Tissue Derived Cells
Therapeutic Represents the First Product to Be Created Using the Company’s Cytotronic™ Platform to Expand and Enhance the Therapeutic Properties of Stem Cells
LOS ANGELES, CA– Oct 27, 2015 – Endonovo Therapeutics, Inc. (OTCQB: ENDV), an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine, announced that it has filed a patent application with the United States Patent and Trademark Office (USPTO) on a perivascular cell mixture created using its proprietary Cytotronics™ Platform that would allow for the wide spread use of cord blood in the treatment of malignant and non-malignant hematological disorders. [Read more…]
Cellipont Bioservices and Wugen Sign Agreement for the Clinical Manufacture of Wugen’s Off-the-shelf CAR-T Cellular Therapies
The Woodlands, TX, and St. Louis, MO, March 14, 2024 – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced the signing of an agreement for the manufacturing of their CAR-T cell therapies. [Read more…]
- « Previous Page
- 1
- …
- 97
- 98
- 99
- 100
- 101
- …
- 334
- Next Page »